United States Patent US 10,912,751: Scope, Claim Boundaries, and Competitive Patent Landscape
US 10,912,751 claims a treatment method for familial hypercholesterolemia using a fixed-dose combination of 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid (often associated in the art with bempedoic acid (BA) as the hydroxy-tetramethylpentadecanedioic acid class) and ezetimibe, at fixed doses of 180 mg BA and 10 mg ezetimibe. The claim set is anchored to (i) indication (familial hypercholesterolemia), (ii) fixed-dose regimen, and (iii) specified biomarker and risk-reduction outcomes.
Below is a structured breakdown of claim scope and the practical patent landscape implications for product formulation, dosing, and design-around strategy.
What does US 10,912,751 claim in plain technical terms?
Core independent claim (Claim 1)
Claim 1 is a method claim defined by a combination product and a clinical context:
- Subject condition: “a subject in need thereof” with familial hypercholesterolemia.
- Treatment modality: administering a fixed-dosed combination of:
- 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid at 180 mg
- Ezetimibe at 10 mg
- Fixed-dose requirement: the combination is “fixed 180 mg” + “fixed 10 mg,” not titratable or variable-dose.
Practical boundary: To infringe Claim 1, a competitor must perform the method steps with a fixed-dose pairing at the claimed numeric doses and for the familial hypercholesterolemia indication.
How do dependent claims narrow scope (and where are the infringement pressure points)?
Biomarker response claims
Claims 2 through 8 add response predicates. Each dependent claim narrows the method to a subset of treated patients or outcomes.
- Claim 2: LDL-C decreases below that of a control receiving placebo.
- Claim 3: hsCRP decreases (no magnitude specified).
- Claim 4: number of very low density lipoprotein decreases.
- Claim 6: LDL-C decreases by at least 30% relative to baseline.
- Claim 7: hsCRP decreases by at least 26% relative to baseline.
- Claim 8: hsCRP decreases by at least 30% relative to baseline.
Infringement pressure points
- Claims 6-8 impose quantitative thresholds that can be outcome-dependent. In practice, these support claims where clinical evidence shows magnitude of change. They also help the patentee argue that treated subjects fall within the claimed response range.
- Claim 2 ties to a placebo comparator rather than only baseline, raising evidentiary questions in litigation but still defining the medical method outcome.
Risk-reduction claim
- Claim 5: administering reduces “risks of cardiovascular diseases.”
Boundary note: “reduces risks” is broader than a numeric effect but still requires a clinical or surrogate framing. The claim likely relies on trial endpoints or accepted risk proxies.
Dosing frequency and dosage form
Claims 9 to 12 add regimen and formulation attributes:
- Claim 9: once daily
- Claim 10: formulated to be a tablet
- Claim 11: formulated for oral delivery
- Claim 12: formulated for administration once daily
Practical boundary
- If a competitor uses once daily oral dosing and tablet form, they are squarely within the regimen/formulation perimeter of the dependent claims. A competitor could attempt to avoid some dependent claim coverage by changing dose frequency (e.g., twice daily) or route (e.g., non-oral), but those changes may conflict with the BA/ezetimibe development pathway and patient adherence targets.
Human subject
- Claim 13: subject is human.
This is a standard narrowing element that excludes non-human use. It is rarely a meaningful design-around.
Where is the real claim “center of gravity”?
The center is Claim 1. Dependent claims add:
- Biomarker and risk outcome predicates (Claims 2-8)
- Regimen and product form (Claims 9-12)
Most litigatable elements
- The fixed-dose pairing and exact numeric doses (180 mg and 10 mg).
- Familial hypercholesterolemia indication.
- Once-daily oral tablet use (dependent, but relevant for product strategy).
- Achieved biomarker/risk endpoints (dependent; outcome-linked scope).
What is the likely scope for “fixed-dose combination” under US practice?
Even without the specification text, the claim language indicates:
- The combination is delivered as a fixed dose (same dosing for the intended regimen).
- It is not necessarily a single dosage form by the word “combination,” but dependent claims expressly call for a tablet (Claim 10) and oral delivery (Claim 11), which indicates the invention is positioned around a practical oral fixed-dose product.
Design implication: A competitor attempting to sell BA and ezetimibe as separate co-packaged products, without a fixed-dose schedule matching the 180 mg/10 mg pairing, may argue non-infringement of “fixed-dosed combination” depending on how the claims are construed.
What does the claim set imply about clinical profile and trial evidence?
The claimed biomarkers align with typical lipid and inflammation modulation arguments:
- LDL-C reduction with a ≥30% relative to baseline threshold (Claim 6).
- hsCRP reduction with ≥26% and ≥30% thresholds (Claims 7-8).
- VLDL reduction (Claim 4).
- A cardiovascular risk reduction statement (Claim 5).
This set suggests that the patent is likely grounded in trial results showing combined lipid and inflammatory benefits versus placebo/control, with specific effect sizes used to support dependent claim narrowing.
Commercial takeaway: the product is designed not only to achieve LDL-C lowering but also to support inflammation and downstream cardiovascular risk narratives that are common in payer and guideline discussions.
How does US 10,912,751 likely overlap with the broader ezetimibe and BA patent landscape?
Ezetimibe landscape
Ezetimibe has extensive patent coverage historically, but those primary patents largely expire. The remaining “live” coverage in the US today tends to be:
- New combinations with other lipid-modifying agents
- New formulations (fixed-dose combination tablets)
- New indications or patient populations
US 10,912,751 fits squarely in combination and population-specific territory (familial hypercholesterolemia).
8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid (BA class) landscape
The BA class (as used in the claim title text) has a development history centered on cholesterol synthesis and ATP-citrate lyase inhibition. Live patent coverage for BA-type compounds typically includes:
- Composition-of-matter (often expiring later depending on filing dates and continuations)
- Specific formulations and fixed-dose products
- Combination regimens with other lipid lowering agents (including ezetimibe)
US 10,912,751 is not framed as a standalone composition-of-matter claim in the excerpt you provided; it is framed as a method-of-treatment using a fixed-dose combination.
Where overlap becomes a clearance risk
Even if a competitor clears the fixed-dose method claims, the overall landscape risk remains in:
- BA composition-of-matter (if still in force)
- BA formulation patents
- Ezetimibe combination patents covering other BA dose levels or other fixed-dose ratios
- IP directed to familial hypercholesterolemia populations
The method claim creates an additional layer of protection beyond generic combination coverage, because it locks in:
- indication
- dose amounts
- once-daily oral tablet administration (dependent)
Competitive patent “attack surfaces”: what can be changed to reduce infringement exposure?
These points map directly to the claim constraints:
1) Dose amounts
- Claim 1 is specifically 180 mg BA + 10 mg ezetimibe.
- If a competitor uses ezetimibe 10 mg but changes BA dose away from 180 mg, they can target non-infringement of the exact fixed-dose pairing.
- If they match BA 180 mg but alter ezetimibe away from 10 mg, Claim 1 also may be avoided.
Risk: even if Claim 1 is avoided, other patents in the same family or related families may cover alternate dose ratios.
2) Indication
Claim 1 requires familial hypercholesterolemia. If a competitor markets for a different indication (even if the same chemistry is used), enforcement depends on:
- how “in need thereof” is construed
- evidence that physicians administer it for familial hypercholesterolemia
- labeling and promotional intent evidence
Risk: real-world practice often tracks clinical indication, so payer-driven switching or label use matters.
3) Regimen frequency and route
Dependent claims:
- once daily (Claims 9 and 12)
- oral delivery (Claim 11)
- tablet formulation (Claim 10)
A competitor could attempt to avoid dependent claim coverage by changing the regimen and/or route, but that can increase development and compliance costs and may conflict with how fixed-dose combo tablets are typically used.
4) Outcome thresholds
Claims 6-8 require achieving certain LDL-C and hsCRP reductions. In enforcement, outcomes can be argued through:
- trial evidence used to support label and medical claims
- real-world endpoints (less certain)
- how the court handles method claims tied to biomarker thresholds
What claim scope does US 10,912,751 likely cover versus close variants?
Likely covered
- Fixed-dose BA 180 mg + ezetimibe 10 mg used once daily in a human with familial hypercholesterolemia, oral tablet administration.
- Treatment regimens showing the claimed biomarker and risk reductions.
Potentially not covered (depending on construction)
- BA and ezetimibe at different fixed dose amounts (even if co-administered).
- Use for non-familial hypercholesterolemia populations.
- Different administration schedule or non-oral/non-tablet formulations (for dependent claim coverage).
Key Takeaways
- US 10,912,751 is a method-of-treatment patent with the defining constraints in Claim 1: familial hypercholesterolemia plus a fixed-dose combination of BA 180 mg and ezetimibe 10 mg.
- Dependent claims add quantitative lipid and inflammation response thresholds (LDL-C ≥30%; hsCRP ≥26% and ≥30%), VLDL reduction, and a cardiovascular risk reduction statement.
- The patent also locks in practical execution elements through dependent claims: once daily dosing and oral tablet formulation.
- Competitive clearance work should treat this as a dose- and indication-specific method shield, layered on top of broader BA and ezetimibe combination coverage.
FAQs
1) Is US 10,912,751 a composition-of-matter patent or a method patent?
It is a method of treating familial hypercholesterolemia by administering a fixed-dose combination of BA and ezetimibe at specified doses.
2) What are the exact dose amounts that define Claim 1?
8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid: 180 mg and ezetimibe: 10 mg.
3) What biomarkers and thresholds appear in the dependent claims?
LDL-C reduction to placebo control (Claim 2) and ≥30% relative to baseline (Claim 6). hsCRP reduction (Claim 3) and ≥26% (Claim 7) and ≥30% (Claim 8) relative to baseline. Also VLDL reduction (Claim 4).
4) Does the patent require once-daily dosing and tablet formulation?
Those are in dependent claims (Claims 9-12). Claim 1 does not explicitly require them, but the broader execution of the method aligns with those constraints.
5) What is the strongest design-around lever?
Change either the fixed-dose numeric pairing (180 mg/10 mg) or the familial hypercholesterolemia treatment context. Dependent claims add more levers around once-daily oral tablet execution and biomarker outcomes.
References
[1] User-provided claim text for US 10,912,751.
